Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis

Autor(es)

Galvis, Marisol Miranda ^{[1, 2]} ; Borges, Gabriel Alvares ^{[3, 2]} ; de Oliveira, Thiago Bueno ^[4] ; de Toledo, Isabela Porto ^[3] ; Castilho, Rogerio Moraes ^{[2, 5]} ; Silva Guerra, Eliete Neves ^{[3, 2]} ; Kowalski, Luiz Paulo ^{[6, 1, 7]} ; Squarize, Cristiane Helena ^{[2, 5]}

Afiliação do(s) autor(es)

^[1] Univ Campinas UNICAMP, Piracicaba Dent Sch, Oral Diag Dept, Piracicaba - Brazil

^[2] Univ Michigan, Sch Dent, Lab Epithelial Biol, Dept Periodont & Oral Med, 1011N Univ Ave, Ann Arbor, MI 48109 - USA

^[3] Univ Brasilia, Hlth Sci Fac, Lab Oral Histopathol, Brasilia, DF - Brazil

^[4] AC Camargo Canc Ctr, Clin Oncol Dept, Sao Paulo - Brazil

^[5] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 - USA

^[6] AC Camargo Canc Ctr, Dept Head & Neck Surg & Otorhinolaryngol, Sao Paulo - Brazil

^[7] Univ Sao Paulo, Med Sch, Head & Neck Surg Dept, Sao Paulo - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY; v. 150, JUN 2020.
• Citações Web of Science: 0

Resumo

Background: Despite multiple modalities used to management of head and neck squamous cell carcinoma (HNSCC), disease control remains unsatisfactory. Immunotherapy is emerging as a novel therapeutic approach. This systematic review assesses clinical data regarding immunotherapy efficacy and safety. Methods: Data from 11 clinical trials testing immunotherapy in HNSCC were assessed. We performed the meta-analysis to correlate the overall survival (OS), response rate (RR), adverse effects, HPV status, and PD-L1 expression. Results: Immunotherapy extended OS (hazard ratio = 0.77, p < 0.0001) and RR significantly (risk ratio = 1.41, p = 0.02). Patients with HPV-positive HNSCC exhibited a better RR (risk ratio = 1.29, p = 0.24) and OS (11.5 vs. 6.3 months). PD-L1 positive tumors showed a higher OS (9.9 vs. 6.5 months). Moreover, immunotherapy caused less adverse effects than standard therapy. Conclusion: Our results indicate the benefit of immunotherapy for improving RR and OS of HNSCC patients. The benefit is higher in patients with HPV and PD-L1 positive tumors. (AU)

• Processo FAPESP: 16/03248-1 - Análise proteômica por espectrometria de massas do carcinoma de células escamosas oral em pacientes jovens
• Beneficiário: Marisol Miranda Galvis
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 17/16347-0 - Análise funcional de proteínas relacionadas ao hpv no carcinoma de células escamosas oral
• Beneficiário: Marisol Miranda Galvis
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Doutorado